

**Oregon CAREAssist
Prior Authorization for Hepatitis C Treatment Regimens**

APPLICATION INFORMATION

Ramsell is the contracted Pharmacy Benefit Manager for Oregon's CAREAssist Program. Requests for the prior authorization of Hepatitis C therapy will be reviewed for completeness of documentation by the Pharmacists in the Ramsell Clinical Department.

Please complete the attached supplemental form for Hepatitis C Treatment Regimens and fax to Ramsell at 1-800-848-4241. The request must include all of the supporting lab results and chart documentation for approval.

PATIENT ELIGIBILITY

- 1) CAREAssist clients who are uninsured. This does not include treatment-naïve patients who have temporary coverage provided by the CAREAssist Bridge Program.
- 2) CAREAssist clients whose primary insurance will not cover the Hepatitis C drugs. The Provider **MUST** appeal the primary denial. The denial and appeal letters **MUST** be faxed to Ramsell alongside the supplemental form.

APPROVAL & NOTIFICATION

Authorization to receive Hepatitis C treatment is dependent upon receipt of complete paperwork, including all medical documentation and proof of appeal, if the client is insured. Clinicians will be notified of the approval decision via fax within 48 hours, Monday through Friday

LIMITS: Treatment for Hepatitis C regimens are limited by program funding. Approval of this application is dependent on availability of CAREAssist funding.

MEDICAL DOCUMENTATION

All supporting laboratory results and chart notes are **REQUIRED:**

- Baseline Complete Blood Count
- Hepatitis C Genotype
- Baseline Hepatitis C RNA viral load (most recent)
- CD4 count (most recent)
- HIV viral load (most recent)

If the patient has cirrhosis, please provide documentation to support the diagnosis of cirrhosis. Some examples include fibrosis staging, liver biopsy results and Child Pugh scoring:

- Fibrosis staging (METAVIR, FibroSure, etc)
- Liver biopsy results
- Child Pugh Score

Additional information: For the latest Hepatitis C treatment recommendations consult the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) Hepatitis C Treatment Guidelines at www.hcvguidelines.org.